Telaprevir Prospects Improve With Positive Findings In Twice-daily Dosing
Vertex reports trial data on hepatitis C candidate show twice-daily dosing efficacy, increased sustained virologic response.
Vertex reports trial data on hepatitis C candidate show twice-daily dosing efficacy, increased sustained virologic response.